Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea for Recalcitrant Macular Edema in CRVO
NCT01857544Phase 4Unknown
- Sponsor
- Tennessee Retina
- Start
- Jun 2013
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in macular edema secondary to central retinal vein occlusion (ME-CRVO), sponsored by Tennessee Retina. Status: unknown.
02
Drugs
aflibercept
03
Conditions
macular edema secondary to central retinal vein occlusion (ME-CRVO)
Beyond the preview
Go deeper on NCT01857544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857544.